Regeneron Pharmaceuticals, Inc.(REGN) Stock Research - Grey Stern Research

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

$631.06 (-0.49%)

REGN Financial Performance


Use the table below to view Regeneron Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $661.00 -
52 Week Low $642.00 -
52 Week High $1211.20 -
Market Cap $71.1 Billion 2/21
Gross Margin 93% 11/21
Profit Margin 24% 6/21
EBITDA margin 26% 6/21
Q3 - 2024 Revenue $3.8 Billion 2/21
Q3 - 2024 Earnings $917.7 Million 2/21
Q3 - 2024 Free Cash Flow $0 Million 20/21
Trailing 4 Quarters Revenue $14.2 Billion 3/21
Trailing 4 Quarters Earnings $4.4 Billion 3/21
Quarterly Earnings Growth -21% 15/21
Annual Earnings Growth 5% 11/21
Quarterly Revenue Growth 10% 14/21
Annual Revenue Growth 5% 15/21
Cash On Hand $0 21/21
Short Term Debt $0 17/21
Long Term Debt $2.0 Billion 3/21

Regeneron Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Regeneron Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 16.10 5/21
PS 5.00 15/21
PB 2.03 18/21
PC -1.00 21/21
Liabilities to Equity 0.08 20/21
ROA 0.12 3/21
ROE 0.13 5/21
Current Ratio 13.50 1/21
Quick Ratio 6.40 2/21
Long Term Debt to Equity 0.06 15/21
Debt to Equity 0.06 16/21
Burn Rate 0.00 14/21
Cash to Cap 0.00 21/21
CCR 20/21
EV to EBITDA 73.77 4/21
EV to Revenue 5.14 14/21

Company Details

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

CEO: Dr. Leonard Schleifer

Website: https://www.regeneron.com

Address: 777 Old Saw Mill River Rd Tarrytown, NEW YORK

Exchange: NASDAQ Global Select

Industry: Biotechnology

Regeneron Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Regeneron Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
ImmunoGen, Inc. IMGN $8.7 Billion
Alnylam Pharmaceuticals, Inc. ALNY $36.5 Billion
BioMarin Pharmaceutical Inc. BMRN $13.6 Billion
Novo Nordisk A/S NVO $327.2 Billion
Ionis Pharmaceuticals, Inc. IONS $5.1 Billion
BeiGene, Ltd. BGNE $20.2 Billion
Incyte Corporation INCY $12.0 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
Sarepta Therapeutics, Inc. SRPT $7.1 Billion
Arrowhead Pharmaceuticals, Inc. ARWR $2.0 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Ultragenyx Pharmaceutical Inc. RARE $3.6 Billion
Madrigal Pharmaceuticals, Inc. MDGL $7.6 Billion
United Therapeutics Corporation UTHR $14.2 Billion
PTC Therapeutics, Inc. PTCT $4.4 Billion
Intellia Therapeutics, Inc. NTLA $903.7 Million
CRISPR Therapeutics AG CRSP $3.5 Billion
Apellis Pharmaceuticals, Inc. APLS $3.0 Billion
Krystal Biotech, Inc. KRYS $5.5 Billion
Prometheus Biosciences, Inc. RXDX $9.6 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
REGN Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 3.8 Billion $917.7 Million
Q3 2024 $ 3.7 Billion $1.3 Billion
Q2 2024 $ 3.5 Billion $1.4 Billion
Q1 2024 $ 3.1 Billion $722.0 Million
Q4 2023 $ 3.4 Billion $1.2 Billion
Q3 2023 $ 3.4 Billion $1.0 Billion
Q2 2023 $ 3.2 Billion $968.4 Million
Q1 2023 $ 3.2 Billion $817.8 Million

View All

REGN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $0 $37.8 Billion $2.0 Billion $35.0 Billion
Q3 2024 $2.0 Billion $37.4 Billion $2.7 Billion $29.3 Billion
Q2 2024 $1.9 Billion $36.1 Billion $2.7 Billion $28.2 Billion
Q1 2024 $2.6 Billion $34.4 Billion $2.7 Billion $27.0 Billion
Q4 2023 $0 $33.1 Billion $2.0 Billion $30.5 Billion
Q3 2023 $2.2 Billion $32.2 Billion $2.7 Billion $24.9 Billion
Q2 2023 $1.9 Billion $30.7 Billion $2.7 Billion $24.0 Billion
Q1 2023 $3.9 Billion $30.1 Billion $2.7 Billion $23.5 Billion

View All

REGN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $1.1 Billion -$183.6 Million $83.6 Million
Q2 2024 $143.1 Million -$210.9 Million -$673.8 Million
Q1 2024 $1.4 Billion -$161.8 Million -$128.0 Million
Q4 2023 $0 $0 $0
Q3 2023 $914.4 Million -$199.9 Million $210.5 Million
Q2 2023 $888.5 Million -$133.9 Million -$2.0 Billion
Q1 2023 $1.1 Billion -$279.1 Million $809.4 Million
Q4 2022 $1.5 Billion -$252.2 Million -$385.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions